Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study.
about
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammationIrritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndromeChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsPharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndromeOlfactory Hallucinations without Clinical Motor Activity: A Comparison of Unirhinal with Birhinal PhantosmiaRecent advances in pharmacological treatment of irritable bowel syndrome.Cannabinoid hyperemesis syndrome.The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity.AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.The successful use of dronabinol for failure to thrive secondary to intestinal dysmotility.Clinical Features and Colonic Motor Disturbances in Chronic Megacolon in Adults.Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traitsHigh body mass alters colonic sensory-motor function and transit in humans.Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide.Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.Measurement of Gastrointestinal and Colonic Motor Functions in Humans and AnimalsEndocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.Peripheral mechanisms in the control of appetite and related experimental therapies in obesity.Comparison of mathematical methods for calculating colonic compliance in humans: power exponential, computer-based and manual linear interpolation models.Examining the roles of cannabinoids in pain and other therapeutic indications: a review.Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies.New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance.Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases.Receptors and ligands role in colon physiology and pathology.Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not "higher".Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.Pharmacogenetics and the treatment of functional gastrointestinal disorders.Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.Cannabinoids and GI Disorders: Endogenous and Exogenous.Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease.Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients.Simplifying the measurement of gastric accommodation using SPECT.The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents.An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions.Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation.Endocannabinoid-related compounds in gastrointestinal diseases.Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial.Towards an Effective Peripheral Visceral Analgesic: Responding to the National Opioid Crisis.
P2860
Q24643922-00081C5E-1AC4-476C-B9BB-8C675D1ADB62Q26860280-17DE52EC-C163-492B-8D39-D727590B7C7DQ28079705-4BA74842-0299-4269-B1DB-C991E4B52CBFQ28244460-4B6667A5-627E-4BCD-841A-DA06671E5AEFQ33772231-CD86CC0E-3A6F-41CD-8C61-4C54B81A34FFQ33958853-A183EA12-3F92-415A-86E5-F36E3C661B86Q34239091-6C242473-7AD8-48D1-978A-5021F302B894Q34464535-35B33CF2-C04D-4C0B-AEB1-AD71973E05D0Q35053292-495EEA0B-58F1-4920-BCDC-98A01C576982Q35484505-F1B2FA79-05A1-436A-B2D3-4266877C2772Q35657772-E7D66792-1AA4-423C-9B57-BC782B54B9D5Q35844591-11A59267-5AC6-482D-879E-864B81343DE7Q36699687-1B55DC4A-5490-481A-8496-7AFC0B3861F5Q36846509-356C0282-3585-40EC-84A8-70E7AE635E3BQ37143573-72A94DD7-747F-421F-982D-936735670776Q37178858-7C921959-A03C-4DD2-B55C-41AE18ADC0E9Q37261844-AA35905C-84BF-48F4-ACA5-CEED175366F1Q37416662-0891B5FB-0BA1-4895-B7B8-B2F761655B01Q37467184-8D211DF3-D91F-404C-AB35-04413DB37071Q37495606-284C62EB-4BBB-45BC-A231-916DAFE4AFB2Q37650292-55626BD8-7F2F-4F43-B55D-7A76EB852A9BQ37960078-0470C84C-D1C9-448A-9A75-707C45AF214FQ38016798-3B6567A5-5BF6-4182-8D6C-6D8B7264AE47Q38072055-CC011791-46B5-4F13-837C-51853BF8861BQ38073798-A005049D-E199-4C09-B780-C73774663303Q38196875-14C35FE6-1384-456B-9018-D139565AEEFEQ38598509-44EB249B-ACCE-4FD9-BB0B-8B1D1D446DB7Q38661352-280B3E29-0DB4-4F18-95FA-08066B516E2FQ38761437-50862EC5-F5B9-424B-84F9-A70D175626A6Q38937293-56933446-94E6-4468-A8D7-B38038035F9DQ38971616-85F53044-5097-409B-9001-1051AB615193Q39213927-01F33D23-F91C-4626-9DEF-BBB103E22A76Q39953399-D2DC4C62-7AAE-4F79-A5C9-F0565E03D26CQ40771921-A33CFAAB-651F-4566-836C-21E1DF673404Q42702028-54109D36-98E2-4415-9FD9-9E35523A3BFDQ46923413-64C88A5A-A5CF-41A3-8911-D6E7F99C6397Q46930478-192CDA2E-1759-4799-ADB3-9649B64BC988Q47839554-5F1ED6CB-E1F1-473A-A511-B6831B024119Q48065211-FEF81E88-AFAE-4E2B-B4E2-935ED3D59649Q52315691-C39BE4C2-F73B-4DDE-8E1E-B707F57D24A3
P2860
Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Effects of a cannabinoid recep ...... zed, placebo-controlled study.
@en
Effects of a cannabinoid recep ...... zed, placebo-controlled study.
@nl
type
label
Effects of a cannabinoid recep ...... zed, placebo-controlled study.
@en
Effects of a cannabinoid recep ...... zed, placebo-controlled study.
@nl
prefLabel
Effects of a cannabinoid recep ...... zed, placebo-controlled study.
@en
Effects of a cannabinoid recep ...... zed, placebo-controlled study.
@nl
P2093
P2860
P921
P356
P1476
Effects of a cannabinoid recep ...... zed, placebo-controlled study.
@en
P2093
Duane Burton
Irene Busciglio
Kari Baxter
Tuba Esfandyari
P2860
P304
P356
10.1152/AJPGI.00565.2006
P577
2007-03-29T00:00:00Z